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Medical control of  abdominal aortic aneurysm 
expansion rate 
To the Editors: 
In the recently published article by Mohammed M. 
Moursi and colleagues, "Inhibition of aortic aneurysm 
devetopment in blotchy mice by beta adrenergic blockade 
independent of altered lysyl oxidase activity" (J Vase Surg 
1995 ;21:792 - 800), the authors extrapolated findings from 
the experimental mouse model to the commonly encoun- 
tered clinical situation of expanding abdominal aortic 
aneurysm (AAA). This article and previously reported 
experimental nd clinical studies have discussed various 
potential mechanisms to account for ~-blocker-related 
attenuation of AAA expansion. 1'2 However, this effect 
remains enigmatic, and several new aspects merit further 
comments. Recently we have demonstrated by in situ 
hybridization the expression ofplasminogen activator (PA) 
genes, namely, tissue type (t-PA) and urokinase type (u-PA), 
and plasminogen activator inhibitor type 1 (PAI-1) within 
macrophage-like cells ofinflammatory infiltrates within the 
wall oflarge AAAs. PA gene expression was colocalized with 
areas of neovascularization within the vascular wall, sug- 
gesting local angiogenesis in response to active pericellular 
fibrinolysis. Increased fibrinolytic capacity in AAA wall may 
also contribute to local proteolytic degradation ofthe aortic 
wall via plasmin generation and activation of metallopro- 
teinases. 30ur  findings support a previous report of in- 
creased PA production in AAA wall 4 and suggest a major 
role for plasminogen activators, assumed to initiate a 
cascade of events, leading to physical weakening of the 
vascular wall and active expansion of the aneurysm. Experi- 
mental and clinical data also have shown the ability of the 
[5-blocker propranolol to reduce plasma fibrinolytic activity 
by blocking circulating t-PA. s-7 It is therefore reasonable to
hypothesize a similar blocking effect on t-PA within the 
aneurysm wall. As treatment ofAAA patients with propra- 
nolol signifieantly slows the rate of aneurysm expansion, 1,2 
our suggested mechanism of PA inhibition may explain the 
observed eceleration effect of propranolol on AAA ex- 
pansion. 
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Regarding "Percutaneous transluminal a gioplasty 
for emboligenic arterial lesions after radiotherapy of  
axillary arteries" 
To the Editors: 
We are writing in regard to your published article 
entitled "Percutaneous transluminal ngioplasty for embo- 
ligenic arterial lesions after adiotherapy ofaxillary arteries" 
by Veyssier-Belot e  al. (J Vasc Surg 1995;22:118-9). The 
authors have reported the good results of percutaneous 
transluminal ngioplasty (PTA) in these kind oflesions. Our 
experience support these data; moreover, we suggest the use 
of endovascular stenting in the presence of fibrotic degen- 
eration of the arterial wall, often complicated by low-grade 
calcifications. The use of intravascular ultrasound (IVUS) 
for accurate intraoperative monitoring of the endovascular 
treatment ofthese particular arterial lesions is also indicated. 
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